2018 ALERT # 15
Investigation of a Legionnaires’ disease Cluster in Lower Washington Heights, Manhattan

Please Share this Alert with All Primary Care, Family Medicine, Emergency Medicine, Internal Medicine, Infectious Disease, Pulmonary Disease, Intensive Care, Laboratory Medicine and Infection Control Staff in Your Facility

- The Health Department is investigating a cluster of 8 confirmed cases of Legionnaires’ disease in the Lower Washington Heights area of Manhattan
  - Providers should have a high index of suspicion for *Legionella* when evaluating patients with respiratory illness or sepsis who live in, work in, or have visited this area of Manhattan during mid-June and early July 2018
- Patients with suspected or confirmed pneumonia should be tested for *Legionella* infection using *both* urine antigen and sputum/respiratory culture.
  - When ordering a sputum culture, alert your laboratory to test for *Legionella* since special microbiologic techniques are required to isolate this organism.
  - The Health Department requires culture data to help identify potential environmental sources of exposure to *Legionella*; urine antigen testing alone does not provide the data needed to make these links.
  - Culture yield is greatest when sputum/respiratory samples are taken early in the patient’s course, but do not delay initiating antimicrobial therapy to obtain cultures.
  - Use a history of geographic exposure to the Lower Washington Heights area in the ten days before developing symptoms to trigger simultaneous urine antigen and culture testing, rather than waiting to send cultures in response to a positive urine antigen test.
- Empiric treatment of pneumonia should include a macrolide or fluoroquinolone that has activity against *Legionella*.
- Report all confirmed or suspect cases of Legionnaire’s Disease to the New York City Health Department

July 11, 2018

Dear Colleagues,

The New York City (NYC) Health Department is investigating a cluster of 8 confirmed cases of Legionnaires’ disease among persons who reside in the Lower Washington Heights area of Manhattan. Symptom onset dates for these patients ranged from 6/26/18 to 7/07/18 and diagnoses were made over the last 7 days. Five patients are ≥ 50 years of age. There have been no deaths associated with this cluster. There are no common sources of exposure among these patients, other than living in the same
area of the city. The Department is currently testing all cooling towers in the affected area to determine
the potential source of exposure.

The DOHMH is requesting that providers test for *Legionella* when evaluating adults with
symptoms of pneumonia using BOTH urine antigen and sputum/respiratory culture, especially if
they report residing, working or visiting (for at least 8 hours) the Lower Washington Heights
and assists the Health Department in detecting and characterizing outbreaks. Testing for and
empirically treating *Legionella* is especially critical for persons at high risk for Legionnaires’ disease,
including persons ≥50 years old, cigarette smokers, and persons with chronic lung disease, or persons
with immunocompromising conditions. The estimated case-fatality rate is 9% for community- acquired
Legionnaires’ disease. Use recommended treatment options for pneumonia as per published guidelines
that include macrolides and fluoroquinolones with activity against *Legionella* species. Do not withhold
empiric therapy for *Legionella* while awaiting *Legionella*-specific testing.

Although urine antigen is a fast and convenient way to diagnose *Legionella* infection, culture data are needed by the Health Department to allow us to link cases to potential environmental sources of exposure to *Legionella*. Please order both tests if the patient has a geographic exposure from living, working, or traveling through the Lower Washington Heights area in the ten days before developing symptoms. If a patient has a positive urine antigen test, please order a sputum/respiratory culture for *Legionella* as soon as possible to maximize yield while the patient is being treated with antibiotics. Do not hold antibiotics to wait for culture results.

Diagnostic Testing
Culture of the organism from respiratory secretions or tissues is the gold standard for diagnosis. Culture has the added benefit of enabling comparison of clinical isolate(s) to environmental isolates to identify a potential source of infection in the setting of a potential outbreak. Please note the following regarding the diagnosis of legionellosis:

- *Legionella* culture requires specialized media (buffered charcoal yeast extract agar (BCYE)). The best specimens for culturing *Legionella* are sputum or bronchoalveolar lavage fluid. Please specifically order a sputum culture for *Legionella* (not a general respiratory bacterial culture) and alert your microbiology laboratory that legionellosis is in your differential diagnosis.

- Urine antigen testing (UAT) is widely available as a rapid method for detecting *Legionella*. UAT is most sensitive for detecting *L. pneumophila* serogroup 1. Although *L. pneumophila* serogroup 1 accounts for most *Legionella* cases, a negative UAT does not rule-out infection due to other *Legionella* species and serotypes. Furthermore, UAT does not allow for molecular comparison of organisms to help determine the environmental source. Providers should also obtain respiratory specimens for culture to diagnose legionellosis in patients with suspected or UAT-confirmed cases.

- Serologic diagnosis is less useful for diagnosing acute infection and requires paired sera, collected 3–4 weeks apart to detect a fourfold rise in antibody titer to a level ≥ 1:128. A single antibody titer is not diagnostic for legionellosis; convalescent serum must be obtained for comparison.

**Recommendations for Providers**
To help the NYC Health Department identify cases of Legionnaires’ disease:
  o Maintain a high index of suspicion for legionellosis among all adults with pneumonia, whether community-acquired or nosocomial.
  o Specifically request both respiratory culture and UAT for *Legionella* detection.
  o Report all suspect and confirmed cases to the Health Department’s Provider Access Line at 1-866-692-3641.
  o Send all *Legionella* isolates to the NYC DOHMH Public Health Laboratory (PHL) for serotyping and molecular testing. Send isolates with the PHL laboratory test request form (available at [http://www1.nyc.gov/assets/doh/downloads/pdf/labs/testing-services.pdf](http://www1.nyc.gov/assets/doh/downloads/pdf/labs/testing-services.pdf)) to:
    
    Public Health Laboratory  
    455 First Ave, Room 136  
    New York, NY 10016  
    
    For laboratory-related questions, please call the PHL Microbiology Section at 212-447-6783.

Additional information on Legionnaires’ disease is available at the Centers for Disease Control and Prevention’s Legionellosis Resource Site: [https://www.cdc.gov/legionella/index.html](https://www.cdc.gov/legionella/index.html). As always, we appreciate your on-going collaboration to help us address infectious disease concerns in the city.

Sincerely,

Demetre C. Daskalakis, MD, MPH  
Deputy Commissioner  
Division of Disease Control